Oncolys BioPharma, Inc.

As of June 30, 2026, Oncolys BioPharma, Inc. carries a market capitalization of 86.62B, placing it among publicly traded companies globally. Its enterprise value stands at 84.24B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Oncolys BioPharma, Inc.'s next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Oncolys BioPharma, Inc. has 29.29M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Oncolys BioPharma, Inc. maintains a current ratio of 3.91, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Oncolys BioPharma, Inc.'s stock has gained approximately 661.90% over the past 52 weeks. The 50-day moving average sits at 5,008.94, while the 200-day moving average is 3,072.25.

As of June 30, 2026, Oncolys BioPharma, Inc. holds 3.19B in cash and equivalents against 799.33M in total debt, resulting in a net debt position of -2.40B. Total book value stands at 3.26B, with working capital of 3.32B providing operational flexibility.